Health Trials

NYSCF Scientific Discovery Biobank

ConditionsALSAmyotrophic Lateral SclerosisAlzheimer DiseaseAlzheimer Disease, Early OnsetAlzheimer Disease, Late OnsetBatten DiseaseCorticobasal DegenerationDementiaFrontotemporal DementiaHuntington DiseaseLewy Body DiseaseMultiple SclerosisMultiple System AtrophyParkinson DiseaseParkinson's Disease and ParkinsonismProgressive Supranuclear PalsyINADDiabetesDiabetes MellitusDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Macular DegenerationOvarian CancerCervical CancerUterine CancerVaginal CancerVulvar CancerPTSDPost Traumatic Stress Disorder
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30+
SponsorNew York Stem Cell Foundation Research Institute

About this trial

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.

Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.

Eligibility criteria

Qualifiers

Age 30 days or older.

Diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest or healthy control.

Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.

Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD/ADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and/or Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.

Disqualifiers

Wards of the state.

For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.

For prospective blood samples: history of coagulation disorder.

For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.

Trial design

Treatments tested in this trial

  • Biological Sample Collection

Treatment groups

10,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

New York Stem Cell Foundation Research Institute

Lead sponsor

Source ClinicalTrials.gov